Humacyte (HUMA) and closely held Pluristyx expanded their partnership to include gene editing to support Humacyte's development of its investigational BioVascular Pancreas using cell lines provided by Pluristyx.
Humacyte's BVP is designed to treat insulin-dependent diabetes.
The expanded partnership builds on Humacyte's existing license of Pluristyx's PluriBank cell lines, the companies said Tuesday in a statement.
Price: 4.50, Change: -0.01, Percent Change: -0.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.